BTIG analysts compiled a list of companies in its coverage that may have potential exposure to SVB Financial (SIVB), either through loan agreements, revolving credit facilities, and/or transactions. The list includes iRhythm Technologies (IRTC), AtriCure (ATRC), ViewRay (VRAY), Treace Medical (TMCI), Vericel (VCEL), Organogenesis (ORGO), Humacyte (HUMA) and Lensar (LNSR). The firm is not changing its estimates or ratings at this time.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- iRhythm provides update on investments with SVB Financial
- iRhythm announces results of multiple new studies at ACC.23/WCC
- Large Real-World Evidence Analysis Demonstrates that Zio® XT Is Associated With the Highest Diagnostic Yield, Lowest Retesting Rates, and Fastest Time to Clinical Diagnosis Compared to Other Ambulatory ECG Monitors
- Four New Studies Featuring Zio® by iRhythm to be Presented at ACC.23/WCC
- iRhythm price target raised to $143 from $135 at Canaccord
